Scholars Central

Conference abstract

Light-enabled drug activation

Authors: Martin Michael Dcona

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Cancer remains one of the major causes of death worldwide and its incidence continues to grow in all age groups. Decades of research has revealed that the cause of the disease is not only because of harmful habits or exposures; but also, due to inherited geneticvariations that contributes to the risk of acquiring it at some point during a personâ??s lifetime. Chemotherapy is one of the treatment modalities that is commonly prescribed to patients with cancer. Treatment with potent drugs entail side-effects that range from hair/ appetite-loss, anemia etc., to fatalities that arise due to its acute toxicity. To address this issue, we devised a simple prodrug-like approach, wherein a cytotoxic drug is coupled to a light sensitive-protecting group known as photocage. Photocaged drug is further coupled to a hydrophilic moiety, which renders the entire conjugate, cell-impermeable. When esophageal cancer cells were treated with this drug-conjugate, it localized outside the cellular membrane. But under light irradiation at an appropriate wavelength, drug was released, permeabilizing into cells and inducing cell-death, thereby increasing the specificity of drug action. We further improved upon specificity, by designing another photocage that coupled folic acid to the photocaged drug. Folic acid binds to folate receptors, which is overexpressed in certain cancers. This conjugate could be used toward targeting tumor tissues with overexpressed folate receptors. Although promising, there are limitations to these designs. Light used in these applications is UVA light, which has several limitations including low skin-penetrability. To address this issue, we used up conversion nanoparticles (UCNPs) that can convert low energy light to a high energy beam, which is sufficient to release drug. In addition, we have designed light-sensitive molecule that mimics the design of combretastatin, a cancer drug. Overall advantage of these approaches is that the small-molecules could also be used to improve efficacy of drugs with minimal to no side-effects.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Pharmaceutica Analytica Acta.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPharmaceutica Analytica Acta
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Martin Michael Dcona”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels